WO2003068812A3 - Immunmodulierendes peptid aus s. aureus enterotoxin b - Google Patents

Immunmodulierendes peptid aus s. aureus enterotoxin b Download PDF

Info

Publication number
WO2003068812A3
WO2003068812A3 PCT/EP2003/001511 EP0301511W WO03068812A3 WO 2003068812 A3 WO2003068812 A3 WO 2003068812A3 EP 0301511 W EP0301511 W EP 0301511W WO 03068812 A3 WO03068812 A3 WO 03068812A3
Authority
WO
WIPO (PCT)
Prior art keywords
seb
immune
peptides
aureus enterotoxin
treating diseases
Prior art date
Application number
PCT/EP2003/001511
Other languages
English (en)
French (fr)
Other versions
WO2003068812A2 (de
Inventor
Karsten Neuber
Original Assignee
Agelab Pharma Gmbh
Karsten Neuber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10207734A external-priority patent/DE10207734A1/de
Priority claimed from DE10240866A external-priority patent/DE10240866A1/de
Application filed by Agelab Pharma Gmbh, Karsten Neuber filed Critical Agelab Pharma Gmbh
Priority to EP03704622A priority Critical patent/EP1476461A2/de
Priority to JP2003567938A priority patent/JP2005531289A/ja
Priority to US10/504,793 priority patent/US20060127411A1/en
Priority to AU2003206900A priority patent/AU2003206900A1/en
Publication of WO2003068812A2 publication Critical patent/WO2003068812A2/de
Publication of WO2003068812A3 publication Critical patent/WO2003068812A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)

Abstract

Die Erfindung betrifft insbesondere Peptide, die spezifisch IgE-Antikörper zu binden vermögen und die beispielsweise aus dem natürlich vorkommenden S. aureus Enterotoxin B (SEB) er­hältlich sind. Ihre immunmodulatorischen Eigenschaften unter­scheiden sich erheblich von denen des bakteriellen SEB. Die erfindungsgemässen Peptide induzieren im Gegensatz zu SEB überraschenderweise keine Proliferation von T-Zellen. Aufgrund ih­rer Eigenschaften sind die Peptide für die Therapie von Er­krankungen geeignet, die durch einen erhöhte Serum-IgE-Spiegel und/oder eine vermehrte Produktion von Interferon-gamma cha­rakterisiert sind, sowie für die Therapie von Erkrankungen, die durch ein Ungleichgewicht von Th1- und Th2-Immunantwort charakterisiert sind, wie z.B. Atopisches Ekzem, Lupus ery­thematodes, Morbus Crohn, Multiple Sklerose, Psoriasis, rheu­matoide Arthritis.
PCT/EP2003/001511 2002-02-15 2003-02-14 Immunmodulierendes peptid aus s. aureus enterotoxin b WO2003068812A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03704622A EP1476461A2 (de) 2002-02-15 2003-02-14 Immunmodulierendes peptid aus s. aureus enterotoxin b
JP2003567938A JP2005531289A (ja) 2002-02-15 2003-02-14 Ｓ．ａｕｒｅｕｓエンテロトキシンＢ由来の免疫調節ペプチド
US10/504,793 US20060127411A1 (en) 2002-02-15 2003-02-14 Immune -modulating peptide made of s.aureus enterotoxin b
AU2003206900A AU2003206900A1 (en) 2002-02-15 2003-02-14 Immune-modulating peptide made of s. aureus enterotoxin b

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10207734A DE10207734A1 (de) 2002-02-15 2002-02-15 Immunmodulierendes Peptid aus S. aureus Enterotoxin B
DE10207734.7 2002-02-15
DE10240866.1 2002-09-04
DE10240866A DE10240866A1 (de) 2002-09-04 2002-09-04 Immunmodulierendes Peptid aus S. aureus Enterotoxin B

Publications (2)

Publication Number Publication Date
WO2003068812A2 WO2003068812A2 (de) 2003-08-21
WO2003068812A3 true WO2003068812A3 (de) 2004-01-08

Family

ID=27735690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001511 WO2003068812A2 (de) 2002-02-15 2003-02-14 Immunmodulierendes peptid aus s. aureus enterotoxin b

Country Status (5)

Country Link
US (1) US20060127411A1 (de)
EP (1) EP1476461A2 (de)
JP (1) JP2005531289A (de)
AU (1) AU2003206900A1 (de)
WO (1) WO2003068812A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
EP2295972A1 (de) * 2009-09-10 2011-03-16 Biomay Ag S. aureus-Allergen
JP5439127B2 (ja) * 2009-11-13 2014-03-12 株式会社さいわいメディカル 乾癬又はアトピー性皮膚炎治療剤
CN103140238B (zh) 2010-07-26 2016-03-16 Qu生物制药公司 免疫原性抗炎组合物
CA2947631A1 (en) 2014-05-02 2015-11-05 Qu Biologics Inc. Anti-microbial immunomodulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BINEK M ET AL: "Localisation of the mitogenic epitope of staphylococcal enterotoxin B.", JOURNAL OF MEDICAL MICROBIOLOGY. ENGLAND MAR 1992, vol. 36, no. 3, March 1992 (1992-03-01), pages 156 - 163, XP009016635, ISSN: 0022-2615 *
DATABASE EMBL [online] 1 May 1997 (1997-05-01), XP002253018, retrieved from EMBL Database accession no. P87432 *
DATABASE EMBL [online] 18 November 1986 (1986-11-18), XP002253016, retrieved from EMBL Database accession no. M11118.1 *
DATABASE EMBL [online] 21 July 1986 (1986-07-21), XP002253017, retrieved from EMBL Database accession no. P01552 *
JETT M ET AL: "Identification of staphylococcal enterotoxin B sequences important for induction of lymphocyte proliferation by using synthetic peptide fragments of the toxin.", INFECTION AND IMMUNITY. UNITED STATES AUG 1994, vol. 62, no. 8, August 1994 (1994-08-01), pages 3408 - 3415, XP002062764, ISSN: 0019-9567 *
JONES C L ET AL: "Nucleotide sequence of the enterotoxin B gene from Staphylococcus aureus.", JOURNAL OF BACTERIOLOGY. UNITED STATES APR 1986, vol. 166, no. 1, M11118.1, April 1986 (1986-04-01), pages 29 - 33, XP009016424, ISSN: 0021-9193, Retrieved from the Internet <URL:EMBL> *
KÖNIG B ET AL: "Responsiveness of peripheral blood mononuclear cells from normal and atopic donors to microbial superantigens.", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY. SWITZERLAND FEB 1995, vol. 106, no. 2, February 1995 (1995-02-01), pages 124 - 133, XP009016461, ISSN: 1018-2438 *
NEUBER K ET AL: "Staphylococcal enterotoxin B affects in vitro IgE synthesis, interferon-gamma, interleukin-4 and interleukin-5 production in atopic eczema.", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY. SWITZERLAND 1995 MAY-JUN, vol. 107, no. 1-3, May 1995 (1995-05-01), pages 179 - 182, XP009016462, ISSN: 1018-2438 *
SOOS J M ET AL: "Multiple binding sites on the superantigen, staphylococcal enterotoxin B, imparts versatility in binding to MHC class II molecules.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 15 JUN 1994, vol. 201, no. 2, 15 June 1994 (1994-06-15), pages 596 - 602, XP002253159, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2003068812A2 (de) 2003-08-21
AU2003206900A1 (en) 2003-09-04
US20060127411A1 (en) 2006-06-15
EP1476461A2 (de) 2004-11-17
JP2005531289A (ja) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2004046306A3 (en) Fully human antibody fab fragments with human interferon-gamma neutralizing activity
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
WO2004020595A8 (en) Novel human polypeptides encoded by polynucleotides
WO2003048327A3 (en) Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
MX2010003574A (es) Anticuerpos il-23.
EP2289550A3 (de) Neutralisierende Antikörper mit ultrahoher Affinität
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
WO2005059106A3 (en) Interferon alpha antibodies and their uses
WO2005003168A3 (en) Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies
MY162559A (en) Human anti-il-23 antibodies, compositions, methods and uses
WO2005000897A3 (en) Antibodies against interleukin-22 and uses therefor
EP2567973A3 (de) IL-21-Antagonisten
WO2004078098A3 (en) Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2004093908A3 (en) Compositions and methods for the therapy of inflammatory bowel disease
WO2004015070A3 (en) Isolation and identification of t cells
WO2016173605A8 (en) Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
WO2003089575A3 (en) Antibodies that specifically bind to tl5
WO2004046332A3 (en) Amplified genes involved in cancer
WO2003068812A3 (de) Immunmodulierendes peptid aus s. aureus enterotoxin b
WO2004075863A3 (en) Cxcr3 antagonists
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO2004094651A3 (en) Novel human polypeptides encoded by polynucleotides
WO2004024768A3 (fr) Anticorps induisant la production de cytokines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003567938

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003704622

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003704622

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2006127411

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10504793

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10504793

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003704622

Country of ref document: EP